ReviewFrontiers in bioengineering and biotechnology2025
Applications of bone regenerative medicine in the foot and ankle: mechanisms, technologies, and therapeutic advances.
Review in Frontiers in bioengineering and biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Foot and ankle diseases significantly impact quality of life, with regenerative medicine emerging as a promising approach. A comprehensive evaluation of both efficacy and safety is paramount for its clinical translation. Methods: A comprehensive literature search was conducted in PubMed using keywords "regenerative medicine" and "foot and ankle" (as of 31 December 2024). Studies were categorized by technology and disease. Results: PRP and HA showed short-term efficacy in talar cartilage repair; stem cells enhanced functional recovery in ankle osteoarthritis. 3D printing enabled personalized implants. Exosomes and AI were identified as future directions. However, the reporting of safety data was often sporadic and non-standardized, highlighting the need for more systematic monitoring in future studies. Conclusion: Regenerative therapies demonstrate potential but require further validation through robust trials that prioritize standardized safety reporting alongside efficacy outcomes. Gaps in exosome isolation, long-term safety, and clinical translation need addressing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.